Clinical efficiency of remote symptom monitoring using electronic patient-reported outcome (ePRO) in lung cancer: Results of the prospective, multicenter REAL-MOOV-LUNG trial.

Abstract

11107 Background: Remote symptom monitoring using electronic patient-reported outcome (ePRO) has been shown to provide clinical benefits and is being implemented for routine care in cancer patients (pts). It may represent a significant operational burden for healthcare providers, that has to be balanced with its actual efficiency in generating clinically meaningful alerts leading to modify pts management. Methods: REAL-MOOV-LUNG is a prospective, multicenter, phase IV trial evaluating the MOOVCARE system in patients (pts) ≥18yo with non-progressive lung cancer, any histology, any stage, who had completed anticancer treatment for < 8weeks (cohort 1), or who were receiving adjuvant, consolidation or maintenance anticancer treatment for ≥8weeks (cohort 2). Primary endpoint was the proportion of patients who had a clinically meaningful modification of the management, predefined as unplanned consultation at the hospital or CT-scan imaging following a MOOVCARE alert. Secondary endpoints included management of alerts, patients and healthcare providers satisfaction, observance, quality-of-life, and survival. Results: From October 2021 to October 2024, 188 pts were enrolled, including 107 men, 81 women, 155 pts with non-small cell lung cancer, 36 with other histologies; 36 pts had oncogene-addicted tumors; 70 pts had metastatic disease, 58 locally-advanced disease, and 60 had early-stage disease. 92% of pts filled at least 1 ePRO questionnaire, median number of questionnaires was 56/pts; 81% of pts had at least 1 alert, median number of alerts was 11, and total number of alerts was 2294. After a median follow-up of 23.9 mo, 39 (21%) pts had a modification of management between 2 scheduled visits, 29 (74%) of which related to preplanned visit, not to an alert; among the remaining 10 (26%) pts, only 5 (13%) pts had clinically meaningful modifications as per the predefined definition. 18-month overall survival was 79.6% [IC95% 73.6%-86.1%]. Conclusions: While adoption of remote symptom monitoring on ePRO was high, with frequent alerts generated from surveys, the actual impact on clinical management of patients with lung cancer was limited in the context of frequent preplanned visits at the hospital as per clinical guidelines. Clinical trial information: NCT04934865 .